Research programme: human polyclonal antibodies - Alere/Medarex/PDL BioPharma

Drug Profile

Research programme: human polyclonal antibodies - Alere/Medarex/PDL BioPharma

Alternative Names: Human polyclonal antibodies research programme - Alere/Medarex/Protein Design Labs

Latest Information Update: 05 Oct 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biosite; Medarex; PDL BioPharma
  • Class Polyclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 29 Sep 2017 Alere has been acquired by Abbott
  • 03 Jul 2006 No development reported - Preclinical for Cancer in USA (unspecified route)
  • 09 Jan 2006 Protein Design Labs is now called PDL BioPharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top